General Information
Drug ID
DR00013
Drug Name
Nilotinib
Synonyms
Nilotinib; Tasigna; AMN107; AMN 107; AMN-107; Nilotinib(AMN-107); Nilotinib (AMN-107); UNII-F41401512X; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide; CHEMBL255863; C28H22F3N7O; HHZIURLSWUIHRB-UHFFFAOYSA-N; NSC747599; MFCD09833716
Drug Type
Small molecular drug
Indication Chronic myelogenous leukemia [ICD11: 2A20.0] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=644241"></iframe>
3D MOL 2D MOL
Formula
C28H22F3N7O
Canonical SMILES
CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
InChI
InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
InChIKey
HHZIURLSWUIHRB-UHFFFAOYSA-N
CAS Number
CAS 641571-10-0
Pharmaceutical Properties Molecular Weight 529.5 Topological Polar Surface Area 97.6
Heavy Atom Count 39 Rotatable Bond Count 6
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 9
XLogP
4.9
PubChem CID
644241
PubChem SID
103358751 , 103939234 , 124749899 , 178101915 , 36454846 , 48169359 , 50111110 , 78899098 , 90341366
ChEBI ID
CHEBI:52172
TTD Drug ID
D00STL
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [2]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [3]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
References
1 Nilotinib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
3 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
4 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.